Tags

Type your tag names separated by a space and hit enter

Rotavirus vaccine: a cost effective control measure for India.
Hum Vaccin Immunother. 2012 Apr; 8(4):501-4.HV

Abstract

Globally, rotavirus diarrhea results in 453,000 deaths in children younger than 5 y—37% of deaths attributable to diarrhea and 5% of all deaths in children younger than 5 y. India alone accounts for 22% (~100,000 deaths) of all deaths attributable to rotavirus infection. Two oral rotavirus vaccines are available: Rotarix, a monovalent P1A[8] G1 vaccine (GlaxoSmithKline), and RotaTeq, a pentavalent bovine-human reassortant vaccine (Merck). Rotarix is administered in a 2-dose schedule with the first and second doses of DTP (DTP1, DTP2). RotaTeq requires a 3-dose schedule with DTP1, DTP2 and DTP3 with an interval of 4–10 weeks between doses. The first dose of either vaccine should be administered to infants aged 6–15 weeks irrespective of the history of previous rotavirus infection, and the maximum age for administering the last dose of either vaccine should be 32 weeks. Although India would require funding from international health organizations/GAVI until new indigenous rotavirus vaccine candidates are developed at a cheaper price, introduction of vaccination into the national immunization program would be a cost-effective step toward control of the rotavirus diarrhea-related morbidity and mortality in India.

Authors+Show Affiliations

Department of Community Medicine, Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India. arun.pgims@gmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

23071989

Citation

Kumar, Arun, et al. "Rotavirus Vaccine: a Cost Effective Control Measure for India." Human Vaccines & Immunotherapeutics, vol. 8, no. 4, 2012, pp. 501-4.
Kumar A, Goel MK, Jain RB, et al. Rotavirus vaccine: a cost effective control measure for India. Hum Vaccin Immunother. 2012;8(4):501-4.
Kumar, A., Goel, M. K., Jain, R. B., Khanna, P., & Vibha, V. (2012). Rotavirus vaccine: a cost effective control measure for India. Human Vaccines & Immunotherapeutics, 8(4), 501-4.
Kumar A, et al. Rotavirus Vaccine: a Cost Effective Control Measure for India. Hum Vaccin Immunother. 2012;8(4):501-4. PubMed PMID: 23071989.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rotavirus vaccine: a cost effective control measure for India. AU - Kumar,Arun, AU - Goel,Manish K, AU - Jain,Ram Bilas, AU - Khanna,Pardeep, AU - Vibha,Vibha, PY - 2012/10/17/entrez PY - 2012/10/17/pubmed PY - 2013/1/8/medline SP - 501 EP - 4 JF - Human vaccines & immunotherapeutics JO - Hum Vaccin Immunother VL - 8 IS - 4 N2 - Globally, rotavirus diarrhea results in 453,000 deaths in children younger than 5 y—37% of deaths attributable to diarrhea and 5% of all deaths in children younger than 5 y. India alone accounts for 22% (~100,000 deaths) of all deaths attributable to rotavirus infection. Two oral rotavirus vaccines are available: Rotarix, a monovalent P1A[8] G1 vaccine (GlaxoSmithKline), and RotaTeq, a pentavalent bovine-human reassortant vaccine (Merck). Rotarix is administered in a 2-dose schedule with the first and second doses of DTP (DTP1, DTP2). RotaTeq requires a 3-dose schedule with DTP1, DTP2 and DTP3 with an interval of 4–10 weeks between doses. The first dose of either vaccine should be administered to infants aged 6–15 weeks irrespective of the history of previous rotavirus infection, and the maximum age for administering the last dose of either vaccine should be 32 weeks. Although India would require funding from international health organizations/GAVI until new indigenous rotavirus vaccine candidates are developed at a cheaper price, introduction of vaccination into the national immunization program would be a cost-effective step toward control of the rotavirus diarrhea-related morbidity and mortality in India. SN - 2164-554X UR - https://www.unboundmedicine.com/medline/citation/23071989/Rotavirus_vaccine:_a_cost_effective_control_measure_for_India_ L2 - http://www.tandfonline.com/doi/full/10.4161/hv.18862 DB - PRIME DP - Unbound Medicine ER -